Home > Rheumatology > EULAR 2020 > Rheumatoid Arthritis > New nanoparticle promising future agent in RA

New nanoparticle promising future agent in RA

A first-in-class therapeutic nanoparticle drug for the specific targeting of anti-citrullinated protein antibodies (ACPAs) has been developed, which may be a promising new therapeutic option for patients with rheumatoid arthritis (RA) [1].

“Several *in vitro* studies have suggested a pathogenic role of ACPAs in RA,” according to Prof. Kira Astakhova (Technical University of Denmark, Denmark) who presented the late-breaking abstract. The authors hypothesised that reducing ACPA levels would have a therapeutic effect by blocking cytokine production. Thus, a series of therapeutic nanoparticles for specific targeting of ACPA in synovial fluid was prepared and tested.

Nanoparticles were prepared by the microdroplet method and then decorated with synthetic cyclic citrullinated peptide aptamer PEP2, PEG/hexanoic acid, and fluorophore (Cy5.5). Nanoparticles were used in a series of *in vitro* assays and *in vivo* studies including disease activity scores, cy...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on